Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Regulating synaptic membrane exocytosis protein 1 (RIMS1) is a multidomain scaffold protein critical for neurotransmitter release at the presynaptic active zone in neurons. As part of the cytomatrix, RIMS1 coordinates docking, priming, and exocytosis of synaptic vesicles by interacting with components including Rab3A, Munc13, voltage-gated calcium channels, and multiple active zone proteins. RIMS1 thus regulates both the probability and timing of neurotransmitter release and is essential for normal synaptic transmission and presynaptic plasticity. Mutations in RIMS1 are causative of cone-rod dystrophy 7, an inherited retinal degenerative disorder. RIMS1 also functions in nonneuronal secretory systems, such as insulin release from pancreatic β-cells and acrosomal exocytosis in sperm.
Drugs or experimental molecules targeting RIMS1 would generally aim to modulate synaptic vesicle release, neurotransmission, or presynaptic calcium channel tethering. Mechanisms could involve inhibition or enhancement of protein-protein interactions in the active zone, or modulation of calcium channel localization.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Regulating synaptic membrane exocytosis protein 1 (RIMS1).